title: [Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection].
abstract: OBJECTIVE
  To evaluate the efficacy of intavitreal injection of bevacizumab in patients with chronic central serous chorioretinopathy.
  
  
  METHODS
  A study of 8 patients with central serous chorioretinopathy who were treated with intravitreal injection of bevacizumab. We studied the visual acuity with Snelleńs method and the foveal thickness, before and after the injection.
  
  
  RESULTS
  The mean age of the patients was 50.25 years. After one month of follow-up, visual acuity before the injection was 0.431 ± 0.249 vision lines and after was 0.631 ± 0.310 vision lines (P=.017).The foveal thickness was 351.25 ± 78.492 μm and after treatment was 183.50 ± 22.640 μm (P=.012).
  
  
  CONCLUSIONS
  Intravitreal bevacizumab can be an alternative treatment in patients with serous central chorioretinopathy as it leads to a better objective visual acuity and foveal thickness with optical coherence tomography.
authors: Servicio de Oftalmología, Hospital Clínico Universitario San Juan de Alicante, España. airengg@hotmail.com
authors: I
authors: I
authors: Gregori-Gisbert
authors: F
authors: F
authors: Aguirre-Balsalobre
authors: J
authors: J
authors: García-Sánchez
authors: G
authors: G
authors: León-Salvatierra
authors: E
authors: E
authors: Mengual-Verdú
authors: J R
authors: JR
authors: Hueso-Abancéns
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000473:pathology; D002908:Chronic Disease; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008266:Macula Lutea / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012160:Retina / Q000473:pathology*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab